- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | AbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira followup | ||
| Fr | In a boon for buyer Bristol-Myers, Celgene's JAK med Inrebic scores FDA nod | ||
| Fr | Investors angry about insulin woes sue Novo Nordisk in Denmark for $1.75B | ||
| Fr | Debt-laden Glenmark counts on assets sales, spinoffs to dig it out | ||
| Fr | Another hit for Roche: UnitedHealthcare backs Amgen biosims over blockbuster oncology meds | ||
| Fr | Bausch may have shed the Valeant name, but it still leans on price hikes: analyst | ||
| Fr | FiercePharmaAsia-Lowest-paid Indian pharma CEO; Dr. Reddy's CRL; Natco's double whammy | ||
| Fr | Roche scores double cancer approval for new Bayer rival Rozlytrek | ||
| Do | Sanofi defends top oncology drug with Jevtana patent win | ||
| Do | Top 10 all-star drugs in 2024: Humira's captain, but who else makes the roster? | ||
| Do | Teva shares approach 20-year low amid Moody's warning and other woes | ||
| Do | Pfizer recalls migraine med Relpax because of bacteria contamination | ||
| Do | Emcure knocked by the FDA for sterility issues after injectable drug recall | ||
| Do | FDA cites solvent recovery firm as a player in the valsartan mess | ||
| Do | Harmony Biosciences scores first approval in narcolepsy med Wakix | ||
| Mi | Novartis' AveXis shifted top scientific leadership before Zolgensma data scandal erupted | ||
| Mi | Regeneron plots $800M New York production push-along with 1,500 new jobs | ||
| Mi | Allergan CEO Saunders lines up for $39M payout after AbbVie buy | ||
| Mi | AstraZeneca, Merck's latest Lynparza combo win could widen its ovarian cancer reach | ||
| Mi | Lawmakers to Teva and Mylan: Stop stonewalling our price-fixing probe | ||
| Mi | Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA | ||
| Mi | Does Stada need Takeda's for-sale European drugs? CEO says no | ||
| Di | Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry | ||
| Di | Novartis names Bulto new U.S. pharma chief as exec reshuffle continues | ||
| Di | Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
